Literature DB >> 20625753

Elevated level of ADAMTS4 in plasma and peripheral monocytes from patients with acute coronary syndrome.

Yanping Zha1, Yong Chen, Fayun Xu, Jie Zhang, Tian Li, Chuanyan Zhao, Lianqun Cui.   

Abstract

OBJECTIVES: A recent study shows that ADAMTS4 is expressed in macrophage-rich areas of human atherosclerotic carotid plaques and coronary unstable plaques, suggesting a pathogenic role of ADAMTS4 in the development of acute coronary syndrome (ACS). We investigated (a) whether the expression level of ADAMTS4 in plasma and peripheral blood mononuclear cells was affected; and (b) whether there was a relationship with hs-CRP level and the stability of coronary atherosclerotic plaque in patients with ACS.
METHODS: Our study included 30 normal controls and 120 patients including 40 with stable angina (SA), 50 with unstable angina (UA), and 30 with acute myocardial infarction (AMI). The expression of ADAMTS4 in monocytes was analyzed by RT-PCR and plasma ADAMTS4 level was determined by ELISA. All coronary stenosis with >30% diameter reduction was assessed by angiographic coronary stenosis morphology.
RESULTS: Patients with ACS showed a significant increase of ADAMTS4 (2.7 ± 0.4) expression in monocytes compared with controls (1.1 ± 0.2) and the SA group (1.3 ± 0.2) (P < 0.001). Plasma ADAMTS4 also showed a higher level in ACS patients (100.2 ± 31.6 ng/ml) than in control (47.5 ± 9.0 ng/ml, P < 0.001) and the SA group (54.3 ± 13.2 ng/ml, P < 0.001). Moreover, we found a positive correlation between hs-CRP and ADAMTS4 expression in monocytes as well as in plasma. There was also a positive correlation of ADAMTS4 expression in monocytes and plasma with complex coronary stenosis (r (1) = 0.61, r (2) = 0.57, P < 0.001).
CONCLUSIONS: Patients with ACS showed increased ADAMTS4 expression, which may aggravate the development of atherosclerosis and instability of atherosclerotic plaques. Therefore, the ADAMTS4 expression may be a valuable marker for predicting the severity of ACS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20625753     DOI: 10.1007/s00392-010-0183-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  32 in total

1.  TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5).

Authors:  M Kashiwagi; M Tortorella; H Nagase; K Brew
Journal:  J Biol Chem       Date:  2001-01-23       Impact factor: 5.157

2.  Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4.

Authors:  J D Sandy; J Westling; R D Kenagy; M L Iruela-Arispe; C Verscharen; J C Rodriguez-Mazaneque; D R Zimmermann; J M Lemire; J W Fischer; T N Wight; A W Clowes
Journal:  J Biol Chem       Date:  2001-01-26       Impact factor: 5.157

Review 3.  MMPs--role in cardiovascular development and disease.

Authors:  Philip R Brauer
Journal:  Front Biosci       Date:  2006-01-01

4.  Aggrecan-versican-neurocan family proteoglycans.

Authors:  R U Margolis; R K Margolis
Journal:  Methods Enzymol       Date:  1994       Impact factor: 1.600

Review 5.  ADAMTS: a novel family of extracellular matrix proteases.

Authors:  B L Tang
Journal:  Int J Biochem Cell Biol       Date:  2001-01       Impact factor: 5.085

Review 6.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

7.  Human abdominal aortic aneurysm is characterized by decreased versican concentration and specific downregulation of versican isoform V(0).

Authors:  A D Theocharis; I Tsolakis; A Hjerpe; N K Karamanos
Journal:  Atherosclerosis       Date:  2001-02-01       Impact factor: 5.162

8.  Quantitative angiographic morphology of coronary stenoses leading to myocardial infarction or unstable angina.

Authors:  R F Wilson; M D Holida; C W White
Journal:  Circulation       Date:  1986-02       Impact factor: 29.690

9.  Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or in stable angina.

Authors:  B Jude; B Agraou; E P McFadden; S Susen; C Bauters; P Lepelley; C Vanhaesbroucke; P Devos; A Cosson; P Asseman
Journal:  Circulation       Date:  1994-10       Impact factor: 29.690

10.  Identification of the proteoglycan versican in aorta and smooth muscle cells by DNA sequence analysis, in situ hybridization and immunohistochemistry.

Authors:  L Y Yao; C Moody; E Schönherr; T N Wight; L J Sandell
Journal:  Matrix Biol       Date:  1994-04       Impact factor: 11.583

View more
  10 in total

1.  Pre- and early in-hospital procedures in patients with acute coronary syndromes: first results of the "German chest pain unit registry".

Authors:  Felix Post; Evangelos Giannitsis; Thomas Riemer; Lars S Maier; Claus Schmitt; Burghard Schumacher; Gerd Heusch; Harald Mudra; Thomas Voigtländer; Rainer Erbel; Harald Darius; Hugo Katus; Christian Hamm; Jochen Senges; Tommaso Gori; Thomas Münzel
Journal:  Clin Res Cardiol       Date:  2012-07-25       Impact factor: 5.460

2.  Identification of Adamts4 as a novel adult cardiac injury biomarker with therapeutic implications in patients with cardiac injuries.

Authors:  Riffat Khanam; Arunima Sengupta; Dipankar Mukhopadhyay; Santanu Chakraborty
Journal:  Sci Rep       Date:  2022-06-14       Impact factor: 4.996

3.  The role of ADAMTS4 and ADAMTS9 in cardiovascular disease in premature ovarian insufficiency and idiopathic hypogonadotropic hypogonadism.

Authors:  S Ozler; E Isci Bostanci; E Oztas; M Kuru Pekcan; B Gumus Guler; N Yilmaz
Journal:  J Endocrinol Invest       Date:  2018-09-05       Impact factor: 4.256

4.  Regulation of ADAMTS-1, -4 and -5 expression in human macrophages: differential regulation by key cytokines implicated in atherosclerosis and novel synergism between TL1A and IL-17.

Authors:  Tim G Ashlin; Alvin P L Kwan; Dipak P Ramji
Journal:  Cytokine       Date:  2013-07-13       Impact factor: 3.861

5.  ADAMTS-4 activity in synovial fluid as a biomarker of inflammation and effusion.

Authors:  S Roberts; H Evans; K Wright; L van Niekerk; B Caterson; J B Richardson; K H S Kumar; J H Kuiper
Journal:  Osteoarthritis Cartilage       Date:  2015-05-21       Impact factor: 6.576

6.  ADAMTS proteases in cardiovascular physiology and disease.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Open Biol       Date:  2020-12-23       Impact factor: 6.411

7.  Atherosclerosis Pathways are Activated in Pericoronary Adipose Tissue of Patients with Coronary Artery Disease.

Authors:  Michał Konwerski; Agnieszka Gromadka; Adam Arendarczyk; Marta Koblowska; Roksana Iwanicka-Nowicka; Radosław Wilimski; Paweł Czub; Krzysztof Jerzy Filipiak; Piotr Hendzel; Piotr Zielenkiewicz; Grzegorz Opolski; Aleksandra Gąsecka; Tomasz Mazurek
Journal:  J Inflamm Res       Date:  2021-10-20

8.  The anti-atherogenic cytokine interleukin-33 inhibits the expression of a disintegrin and metalloproteinase with thrombospondin motifs-1, -4 and -5 in human macrophages: Requirement of extracellular signal-regulated kinase, c-Jun N-terminal kinase and phosphoinositide 3-kinase signaling pathways.

Authors:  Tim G Ashlin; Melanie L Buckley; Rebecca C Salter; Jason L Johnson; Alvin P L Kwan; Dipak P Ramji
Journal:  Int J Biochem Cell Biol       Date:  2013-11-22       Impact factor: 5.085

9.  Integrative computational and experimental approaches to establish a post-myocardial infarction knowledge map.

Authors:  Nguyen T Nguyen; Xiaolin Zhang; Cathy Wu; Richard A Lange; Robert J Chilton; Merry L Lindsey; Yu-Fang Jin
Journal:  PLoS Comput Biol       Date:  2014-03-20       Impact factor: 4.475

10.  Loss of ADAMTS4 reduces high fat diet-induced atherosclerosis and enhances plaque stability in ApoE(-/-) mice.

Authors:  Saran Kumar; Mo Chen; Yan Li; Fiona H S Wong; Chung Wee Thiam; Md Zakir Hossain; Kian Keong Poh; Satoshi Hirohata; Hiroko Ogawa; Véronique Angeli; Ruowen Ge
Journal:  Sci Rep       Date:  2016-08-05       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.